115 related articles for article (PubMed ID: 950467)
1. In vitro activation of mouse macrophages by rat lymphocyte mediators.
Fidler IJ; Darnell JH; Budmen MB
J Immunol; 1976 Aug; 117(2):666-73. PubMed ID: 950467
[TBL] [Abstract][Full Text] [Related]
2. Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A.
Fidler IJ; Darnell JH; Budmen MB
Cancer Res; 1976 Oct; 36(10):3608-15. PubMed ID: 953987
[TBL] [Abstract][Full Text] [Related]
3. Studies on macrophage-activating factor (MAF) in antitumor immune responses. I. Tumor-specific Lyt-1+2- T cells are required for producing MAF able to generate cytolytic as well as cytostatic macrophages.
Nakajima H; Fujiwara H; Takai Y; Izumi Y; Sano S; Tsuchida T; Hamaoka T
J Immunol; 1985 Sep; 135(3):2199-205. PubMed ID: 3894520
[TBL] [Abstract][Full Text] [Related]
4. Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes.
Poste G; Kirsh R; Fogler WE; Fidler IJ
Cancer Res; 1979 Mar; 39(3):881-92. PubMed ID: 427777
[TBL] [Abstract][Full Text] [Related]
5. The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes.
Fidler IJ; Raz A; Fogler WE; Hoyer LC; Poste G
Cancer Res; 1981 Feb; 41(2):495-504. PubMed ID: 7004633
[TBL] [Abstract][Full Text] [Related]
6. Synergistic activation by lymphokines and muramyl dipeptide of tumoricidal properties in rat alveolar macrophages.
Sone S; Fidler IJ
J Immunol; 1980 Dec; 125(6):2454-60. PubMed ID: 7430635
[TBL] [Abstract][Full Text] [Related]
7. Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines.
Sone S; Poste G; Fidler IJ
J Immunol; 1980 May; 124(5):2197-202. PubMed ID: 7365253
[TBL] [Abstract][Full Text] [Related]
8. Macrophages activated in vitro with lymphocyte mediators kill neoplastic but not normal cells.
Piessens WF; Churchill WH; David
J Immunol; 1975 Jan; 114(1 Pt 2):293-9. PubMed ID: 163856
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
Fidler IJ; Bucana C
Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
[TBL] [Abstract][Full Text] [Related]
10. Regulatory role of humoral factors released by macrophages in rat lymphocyte reactivity in vitro. I. Influence of humoral factors released by sensitized peritoneal macrophages on normal lymphocyte reactivity.
Brajczewska-Fischer W; Ryzewska AG
Arch Immunol Ther Exp (Warsz); 1980; 28(1):19-26. PubMed ID: 6968190
[TBL] [Abstract][Full Text] [Related]
11. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
12. Studies on the mechanisms of action of the immunomodulator Bestatin in various screening test systems.
Schorlemmer HU; Bosslet K; Dickneite G; Lüben G; Sedlacek HH
Behring Inst Mitt; 1984 May; (74):157-73. PubMed ID: 6383322
[TBL] [Abstract][Full Text] [Related]
13. Differential cytotoxicity of activated lymphocytes on allogeneic and xenogeneic target cells. III. Species specificity of lymphocyte target cell recognition in vitro.
Stejskal V; Perlmann P
Eur J Immunol; 1976 May; 6(5):347-52. PubMed ID: 991906
[TBL] [Abstract][Full Text] [Related]
14. Tumor target-derived soluble factor synergizes with IFN-gamma and IL-2 to activate macrophages for tumor necrosis factor and nitric oxide production to mediate cytotoxicity of the same target.
Jiang H; Stewart CA; Fast DJ; Leu RW
J Immunol; 1992 Sep; 149(6):2137-46. PubMed ID: 1517576
[TBL] [Abstract][Full Text] [Related]
15. Macrophages as effector cells of protective immunity in murine schistosomiasis. VI. T cell-dependent, lymphokine-mediated, activation of macrophages in response to Schistosoma mansoni antigens.
James SL; Lazdins JK; Hieny S; Natovitz P
J Immunol; 1983 Sep; 131(3):1481-6. PubMed ID: 6350456
[TBL] [Abstract][Full Text] [Related]
16. Preparation and antitumor effect of macrophage activating factor (MAF) encapsulated in liposomes bearing a monoclonal anti-human melanoma (A375) antibody.
Watanabe Y; Uchida E; Higuchi M; Imai Y; Osawa T
J Biol Response Mod; 1987 Oct; 6(5):556-68. PubMed ID: 3316511
[TBL] [Abstract][Full Text] [Related]
17. Macrophage tumoricidal activity as a possible antitumor mechanism associated with the local injection of allogeneic spleen cells into rats.
Kawase I; Komuta K; Namba M; Yokota S; Ogura T; Kishimoto S
Cancer Res; 1986 Mar; 46(3):1047-54. PubMed ID: 3510719
[TBL] [Abstract][Full Text] [Related]
18. Rapid decay of tumoricidal activity and loss of responsiveness to lymphokines in inflammatory macrophages.
Poste G; Kirsh R
Cancer Res; 1979 Jul; 39(7 Pt 1):2582-90. PubMed ID: 87267
[TBL] [Abstract][Full Text] [Related]
19. Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases.
Fidler IJ; Schroit AJ
J Immunol; 1984 Jul; 133(1):515-8. PubMed ID: 6373933
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte supernatant-induced human monocyte tumoricidal activity: dependence on the presence of gamma-interferon.
Sadlik JR; Hoyer M; Leyko MA; Horvat R; Parmely M; Whitacre C; Zwilling B; Rinehart JJ
Cancer Res; 1985 May; 45(5):1940-5. PubMed ID: 3921233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
